Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115368) titled 'Study of GS-1219 in Participants With HIV-1' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Gilead Sciences
Condition:
HIV-1-infection
Intervention:
Drug: GS-1219
Drug: BVY
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 2025
Target Sample Size: 30
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07115368
Disclaimer: Curated by HT Syndication....